AZD7507 free base · Synonyms: AZD-7507 · AZD 7507

AZD7507 is a potent and orally active CSF-1R inhibitor.

For research use only. Not for human or veterinary use.

Target c-Fms

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

AZD7507 structure

CAS No.: 1041852-85-0

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
100 mg	USD 458.00	BP-01835-100mg	In stock	Get quote
250 mg	USD 688.00	BP-01835-250mg	In stock	Get quote
500 mg	USD 1,050.00	BP-01835-500mg	In stock	Get quote
1 g	USD 1,520.00	BP-01835-1g	In stock	Get quote
5 g	Inquire	BP-01835-5g	Inquire	Inquire

Need another size or custom synthesis? Request a quote.

Description

AZD7507 is a potent and orally active CSF-1R inhibitor, with antitumor activity.

Biological activity

In Vitro AZD7507 (Compound 31) inhibits the proliferation of 3T3 cells engineered to express CSF-1R and stimulated with CSF-1 (IC50, 32 nM), shows inhibitory activity against hERG and NaV1.5, with IC50s of >30 and 26 μM. In Vivo AZD7507 has good rat oral PK, with in vivo clearance of 7 mL/min/kg and 42% bioavailability. In the canine L-type Ca channel assay, the IC50 is >20 μM[1]. AZD7507 significantly decreases the number of CD68+ macrophages in mice, and also reduces the volume and mass in mice bearing CC-LP-1 and SNU-1079 cells, but not WITT-1 cells.

Identifiers

SMILES: COC1=CC2=NN=C(C(N)=O)C(NC3=CC=C(C)C=C3F)=C2C=C1N1CCN(CCO)CC1
InChIKey: CPDGCAFPSYOTGO-UHFFFAOYSA-N

Specifications

MW (average): 454.4973
Formula: C₂₃H₂₇FN₆O₃
CAS No.: 1041852-85-0
Physical state: Solid
Color: Light yellow to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

Documents

References

[1]. Scott DA, et al. Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4591-6.

[2]. Boulter L, et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. Send to J Clin Invest. 2015 Mar 2;125(3):1269-85.

Same target

Search c-Fms

BP-01910 DCC-3014 free base · >98%

Same research area

Search Cancer